Programmed-death 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors have shown promising results in recent clinical trials in metastatic renal cell carcinoma (mRCC), according to data presented at the Hong Kong Society of Uro-Oncology Annual Scientific Meeting.
Adding docetaxel to androgen deprivation therapy (ADT) can prevent prostate-specific antigen (PSA) progression and delay the development of castration resistance in Chinese patients with metastatic hormone-naïve prostate cancer, a study by the Chinese University of Hong Kong (CUHK) has shown.
Findings of recently completed trials have shown that atezolizumab and pembrolizumab could be possible first-line therapy options for cisplatin-ineligible patients with advanced and metastatic urothelial carcinoma, according to a presentation at the Hong Kong Society of Uro-Oncology Annual Scientific Meeting 2018.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.